Table 2

Outcomes and resource utilization
Patient characteristics and outcomes ICU + IA patients (N = 412)
Length of stay (days), Mean (SD); (min – max) 26.9 (25.0); (1.0 – 269.0)
 Survivors length of stay, Mean (SD); (min – max) 29.2 (28.2); (4.0 – 269.0)
 Non-survivors length of stay, Mean (SD); (min – max) 24.2 (20.4); (1.0 – 121.0)
Hospital ICU stay (days), Mean (SD); (min – max) 15.8 (15.3); (1 – 114.0)
Re-hospitalization 1, n (%) 5 (1.21%)
Mortality within hospital, n (%) 188 (45.63%)
 Expired within 30 days of hospitalization, n (%) 117 (33.05%)
No. of patients with at least one day on mechanical ventilation, n (%) 298 (72.33%)
 Length of mechanical ventilation (days), Mean (SD); (min – max) 16.5 (15.8); (1.0 – 111.0)
No. of patients with bronchoscopy (%) 60 (14.56%)
No. of patients with needle biopsy (%) 221 (53.64%)
Antifungal Therapies
Index Event (IE) Day 2 , Mean (SD); (min – max) 8.6 (9.2); (1.0 – 85.0)
No. of Antifungal therapies per patient, Mean (SD); (min – max) 1.70 (0.81); (1.00 – 4.00)
Length of Antifungal therapy (days), Mean (SD); (min – max) 14.6 (13.0); (1.0 – 122.0)
 Length of therapy (Survivors) 16.3 (12.8); (5.0 – 122.0)
 Length of therapy (Non-survivors) 12.6 (13.1); (1.0 – 93.0)

1 Re-hospitalization to the same hospital, within 4 months of discharge.

2 Index Event Day = Inpatient day when the antifungal therapy was initiated.

ICU, intensive care unit; IA, invasive aspergillosis.

Baddley et al.

Baddley et al. BMC Infectious Diseases 2013 13:29   doi:10.1186/1471-2334-13-29

Open Data